[PR Newswire] – NORTH CHICAGO, Ill., June 6, 2016 /PRNewswire/ — Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced longer-term follow-up results from Phase 3 studies of IMBRUVICA® (ibrutinib) … Read more on this. AbbVie Inc. (ABBV) , with a current market cap of $100.72B, opened this morning at $62.13. Looking at the equity, the company’s one day range is $61.87 to $62.97 and has traded between $45.45 and $71.60 over the past 12 months. Priced at 13.66x this year’s forecasted earnings, ABBV shares are relatively expensive compared to the industry’s -0.21x forward p/e ratio. And for dividend hunters, the company pays shareholders $2.28 per share annually in dividends, yielding 3.51%. In a review of the consensus earnings estimate this quarter, 17 sell-side analysts are looking at $1.20 per share, which would be $0.12 better than the year-ago quarter and a $0.04 sequential decrease. Furthermore, our analysis shows the full-year EPS estimate to be $4.76, which would be a $0.47 improvement when compared to the last year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $6.20 Billion. If realized, that would be a 13.14% increase over the year-ago quarter. Recently, Societe Generale Initiated ABBV at Sell (Apr 6, 2016). Previously, Deutsche Bank Initiated ABBV at to Hold. The average price target for ABBV shares is $71.06, which is 14.37% above where the stock opened this morning. See more in (NYSE:ABBV) Similar Articles: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Demonstrates Progress in Oncology Research at ASCO 2016 Annual Meeting with Multiple Abstracts Evaluating Eight Medicines Across Cancer Types Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirr Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie’s Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia